NCT03540901View on ClinicalTrials.gov

Effect of Acetazolamide on Lung Water Content by Ultrasound in Patients With Respiratory Disease at Altitude

PHASE4CompletedINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

May 22, 2018

Primary Completion Date

August 2, 2018

Study Completion Date

August 2, 2018

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG

ACETAZOLAMIDE oral capsule

Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3100m

DRUG

Placebo oral capsule

Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3100m

Trial Locations (1)

720040

National Center of Cardiology and Internal Medicine, Bishkek

All Listed Sponsors
collaborator

National Center of Cardiology and Internal Medicine named after academician M.Mirrakhimov

OTHER_GOV

lead

University of Zurich

OTHER

NCT03540901 - Effect of Acetazolamide on Lung Water Content by Ultrasound in Patients With Respiratory Disease at Altitude | Biotech Hunter | Biotech Hunter